Vor bio announces retirement of chief medical officer

Cambridge, mass., april 14, 2022 (globe newswire) -- vor bio (nasdaq: vor), a clinical-stage cell and genome engineering company, today announced that dr. christopher slapak, chief medical officer for vor bio plans to retire. the vor bio clinical team is fully resourced and continues to actively recruit patients into vbp101, the company's phase 1/2a first-in-human study of vor33 in patients with aml who are at high risk of relapse. an executive search to replace dr. slapak is underway.
VOR Ratings Summary
VOR Quant Ranking